Psychiatry AtlasMedication guide · United States

Sleep medicine that reduces wake signals

Daridorexant (Quviviq)

Generic name
daridorexant (as daridorexant hydrochloride)
Brand names
Quviviq
Medication class
Sleep medicine that reduces wake signals
Forms covered
Quviviq oral tablets

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Daridorexant (Quviviq) treats adult insomnia involving difficulty falling asleep, staying asleep or both. It reduces the effect of orexin, a brain signal involved in wakefulness.

What to expect: The intended result is better sleep with acceptable daytime alertness.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Insomnia with sleep-onset and/or sleep-maintenance difficulty — Adults. Pediatric safety and effectiveness are not established.Quviviq oral tablets.

What should I expect?

The intended result is better sleep with acceptable daytime alertness. Next-day sleepiness is still possible, including when the medicine is taken as directed.

If insomnia persists after 7–10 days or gets worse, contact the prescriber for reassessment. Do not respond to a poor night by adding an extra dose or another sleeping medicine.

How do I take it safely?

Take no more than once nightly, within 30 minutes before bed, with at least seven hours before planned awakening. Food can delay the effect. Skip a missed bedtime dose if seven hours are no longer available; never double or take a daytime catch-up dose.

Avoid alcohol and unreviewed sedatives or other insomnia medicines. Do not drive or do hazardous tasks while impaired, including the next day. Store securely and never share.

Do not use with narcolepsy or a previous allergy to Quviviq. Discuss depression, suicidal thoughts, breathing disease, falls and liver disease. Moderate liver impairment requires a lower maximum; severe impairment is not a recommended-use setting.

Strong CYP3A4 inhibitors and strong or moderate inducers should be avoided; moderate inhibitors require a lower dose. Quviviq can also raise levels of certain other medicines, so the whole regimen needs review.

Stop and contact the prescriber immediately if sleepwalking, sleep-driving or other activity while not fully awake occurs. Report sleep paralysis, sleep-related hallucinations or sudden weakness.

Discuss pregnancy and breastfeeding. A small study found low milk levels after one dose, but effects on infants are unknown; monitor for excessive sedation. Pediatric use is not established, and older adults remain vulnerable to falls.

What side effects should I know about?

  • Headache, sleepiness or fatigue, dizziness and nausea are reported adverse reactions. Unusual dreams and sleep paralysis can also occur.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Stop and contact the prescriber immediately for sleepwalking, sleep-driving or other activities while not fully awake.
  • Report sleep paralysis, vivid hallucinations while falling asleep or waking, sudden muscle weakness, or dangerous next-day impairment. Do not drive while impaired.
  • New suicidal thoughts or a severe mood or behavior change needs immediate clinical contact; get emergency help if someone cannot stay safe.
  • Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.

What else should I know to stay safe?

  • Do not use with narcolepsy or previous Quviviq allergy. Review breathing disease, depression, substance-use history, falls and liver disease. Moderate liver impairment requires a lower maximum; severe impairment is not a recommended-use setting.
  • Avoid alcohol and unreviewed sedatives or sleep medicines. Strong CYP3A4 inhibitors and strong or moderate inducers should be avoided; moderate inhibitors require a lower dose. Quviviq can also raise levels of other medicines. Do not drive while impaired; store securely and never share.
  • Discuss pregnancy and breastfeeding. Low milk levels after a single dose do not establish infant safety; monitor for excessive infant sedation. Older adults remain vulnerable to falls, and pediatric use is not established.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • A shorter half-life than some related medicines does not guarantee safe driving the next morning. Individual impairment still matters.
  • The tablet may take longer to act after food; that is not a reason to repeat the dose.
  • No withdrawal syndrome was seen in the reviewed trials, but misuse risk and recurrence of insomnia still warrant follow-up.

How does it work?

Daridorexant reduces the influence of orexin, a chemical messenger that helps keep the brain awake. It prevents orexin from activating its receiving sites, which can make sleep easier to begin and maintain. The medicine changes one part of the system controlling sleep and wakefulness.

Explore medication science

How was this medicine developed?

The FDA approved Quviviq on January 7, 2022. Its development studied blocking both orexin receptors to improve sleep onset and maintenance. The medicine subsequently became a Schedule IV controlled product.

How do I say the name?

Daridorexant: DAR-ih-doh-REX-ant. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. daridorexant: current US prescribing information
  2. daridorexant: FDA approval history
  3. daridorexant: patient medicine information
  4. Daridorexant
  5. Quviviq: Package Insert / Prescribing Information / MOA
  6. daridorexant: FDA prescribing information
  7. lemborexant: current prescribing information
  8. Rozerem: current prescribing information
  9. Daridorexant: verified neutral parent, PubChem CID 91801202
  10. Schizophrenia
  11. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top